UK Pulmonary Arterial Hypertension Market Size & Outlook
UK pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
UK pulmonary arterial hypertension market highlights
- The UK pulmonary arterial hypertension market generated a revenue of USD 380.2 million in 2023 and is expected to reach USD 518.1 million by 2030.
- The UK market is expected to grow at a CAGR of 4.5% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- PDE-5 Inhibitors is the most lucrative drug class segment registering the fastest growth during the forecast period.
Pulmonary arterial hypertension market data book summary
| Market revenue in 2023 | USD 380.2 million |
| Market revenue in 2030 | USD 518.1 million |
| Growth rate | 4.5% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | PDE-5 Inhibitors |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, UK accounted for 5.2% of the global pulmonary arterial hypertension market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany pulmonary arterial hypertension market is projected to lead the regional market in terms of revenue in 2030.
- Sweden is the fastest growing regional market in Europe and is projected to reach USD 133.7 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 47.19% in 2023. Horizon Databook has segmented the UK pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
The rise in geriatric population is a major demographic trend observed in the European Region. A rise in chronic health problems across the aging demographic has increased the demand of solutions for cardiovascular disorder providers including PAH.
The country has a global healthcare system where majority of the people is covered under national healthcare centers by free healthcare services. As a result, government healthcare facilities are the only target customers for major market players offering usage in the country.
An estimated 3 million in the UK have a rare disease. Increasing awareness about rare diseases in the country is likely to further promote market growth. For instance, on Rare Disease Day in 2020, Takeda UK gathered 13 patient groups for its rare disease awareness campaign. The campaign I am Number 17 tried to generate awareness about the fact that one in 17 people in the country is likely to be affected by a rare disease at some point in their lives.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK pulmonary arterial hypertension market size, by drug class, 2018-2030 (US$M)
UK Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
